Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. META
10. TLT

Go back to Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
(NASDAQ: SYRE) Delayed: 92.68 +1.51 (1.66%)
Previous Close $91.17    52 Week High $ 
Open $92.86    52 Week Low $ 
Day High $95.19    P/E N/A 
Day Low $91.14    EPS $ 
Volume 1,438,895